Posted by Michael Wonder on 07 Apr 2017
Innocrin Pharmaceuticals granted fast track designation by FDA for seviteronel treatment of women with triple-negative breast cancer and women or men with estrogen receptor-positive breast cancer
6 April 2017 - Innocrin has announced that the FDA granted a second fast track designation for seviteronel (VT-464).
The new designation is for the treatment of women with advanced AR+ triple-negative breast cancer and women or men with advanced oestrogen receptor-positive breast cancer.
“We believe that the award of a second fast track designation for seviteronel, in addition to men with castration resistant prostate cancer (CRPC), is continued FDA recognition of the compound’s potential to address significant unmet medical need in hormone-dependent cancers,” stated Dr. Eshelman.
